Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes

Kashif M Munir,1 Stephen N Davis2 1Division of Endocrinology, Diabetes, and Nutrition, Center for Diabetes and Endocrinology, 2Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: With rates of obesity and diabetes rising across the world, effective therap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Munir KM, Davis SN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	empagliflozin type 2 diabetes hemoglobin A1c glucose body weight Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/de0b37de21c147caa6d1c75c365dd912
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de0b37de21c147caa6d1c75c365dd912
record_format	dspace
spelling	oai:doaj.org-article:de0b37de21c147caa6d1c75c365dd9122021-12-02T00:12:04ZDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetes1179-1438https://doaj.org/article/de0b37de21c147caa6d1c75c365dd9122016-04-01T00:00:00Zhttps://www.dovepress.com/differential-pharmacology-and-clinical-utility-of-empagliflozin-in-typ-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Kashif M Munir,1 Stephen N Davis2 1Division of Endocrinology, Diabetes, and Nutrition, Center for Diabetes and Endocrinology, 2Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: With rates of obesity and diabetes rising across the world, effective therapies to treat hyperglycemia and its associated comorbidities continue to be in demand. Empagliflozin is a highly selective sodium glucose transporter-2 inhibitor that improves serum glucose levels by inducing glucosuria. Taken orally, it is rapidly absorbed with linear pharmacokinetics consistent in Asian and Caucasian populations. Empagliflozin treatment demonstrates consistent reductions in hemoglobin A1c, fasting plasma glucose, body weight, and blood pressure in individuals with type 2 diabetes. Improvements in glycemic control and metabolic end points are evident with empagliflozin monotherapy, as add-on to oral hypoglycemics or add-on to insulin. The nonglycemic effects of empagliflozin with consistent improvements in blood pressure, body weight, and waist circumference provide additional rationale for use in patients with type 2 diabetes. Moreover, treatment with empagliflozin has recently shown significant reductions in both microvascular and macrovascular complications of diabetes. Keywords: empagliflozin, type 2 diabetes, pharmacology, blood pressure, body weight, hemoglobin A1c, glucoseMunir KMDavis SNDove Medical Pressarticleempagliflozintype 2 diabeteshemoglobin A1cglucosebody weightTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2016, Iss Issue 1, Pp 19-34 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	empagliflozin type 2 diabetes hemoglobin A1c glucose body weight Therapeutics. Pharmacology RM1-950
spellingShingle	empagliflozin type 2 diabetes hemoglobin A1c glucose body weight Therapeutics. Pharmacology RM1-950 Munir KM Davis SN Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
description	Kashif M Munir,1 Stephen N Davis2 1Division of Endocrinology, Diabetes, and Nutrition, Center for Diabetes and Endocrinology, 2Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: With rates of obesity and diabetes rising across the world, effective therapies to treat hyperglycemia and its associated comorbidities continue to be in demand. Empagliflozin is a highly selective sodium glucose transporter-2 inhibitor that improves serum glucose levels by inducing glucosuria. Taken orally, it is rapidly absorbed with linear pharmacokinetics consistent in Asian and Caucasian populations. Empagliflozin treatment demonstrates consistent reductions in hemoglobin A1c, fasting plasma glucose, body weight, and blood pressure in individuals with type 2 diabetes. Improvements in glycemic control and metabolic end points are evident with empagliflozin monotherapy, as add-on to oral hypoglycemics or add-on to insulin. The nonglycemic effects of empagliflozin with consistent improvements in blood pressure, body weight, and waist circumference provide additional rationale for use in patients with type 2 diabetes. Moreover, treatment with empagliflozin has recently shown significant reductions in both microvascular and macrovascular complications of diabetes. Keywords: empagliflozin, type 2 diabetes, pharmacology, blood pressure, body weight, hemoglobin A1c, glucose
format	article
author	Munir KM Davis SN
author_facet	Munir KM Davis SN
author_sort	Munir KM
title	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
title_short	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
title_full	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
title_fullStr	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
title_full_unstemmed	Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
title_sort	differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/de0b37de21c147caa6d1c75c365dd912
work_keys_str_mv	AT munirkm differentialpharmacologyandclinicalutilityofempagliflozinintype2diabetes AT davissn differentialpharmacologyandclinicalutilityofempagliflozinintype2diabetes
_version_	1718403895867211776

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes

Ejemplares similares